InMed Pharmaceuticals Inc.
INMHealthcare|Drug Manufacturers - Specialty & Generic|CA
$15.56
+2.35 (+17.79%)
Cash / Share
$2074.83
Financials
Financial Snapshot
Market Cap
$8.5M
Enterprise Value
-$1.09B
Revenue (TTM)
$2.06B
Net Income (TTM)
-$13.2M
Cash & Investments
$1.13B
Net Cash
$1.13B
Free Cash Flow (TTM)
-$1.15B
Operating CF (TTM)
-$1.15B
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$1.13B
Quarterly Burn
$287.6M
Monthly Burn
$95.9M
Est. Runway
~3.9 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.2M | $20.1M | $13.7M | $5.8M | $9.2M | $8.0M | $11.8M | $9.0M | $15.1M | $2.2M | $1.13B | |
| Operating Cash Flow | -$2.4M | -$3.7M | -$6.7M | -$7.4M | -$9.8M | -$15.6M | -$7.3M | -$7.0M | -$7.8M | -$8.64B | -$1.15B | |
| Free Cash Flow | -$2.4M | -$3.7M | -$6.7M | -$7.4M | -$9.8M | -$15.6M | -$7.4M | -$7.0M | -$7.8M | -$8.64B | -$1.15B | |
| Capital Expenditure | -$19.5K | -$43.8K | -$27.0K | -$42.6K | -$1.7K | -$39.1K | -$161.8K | -$9.3K | $0.00 | $3.00 | $9.49 | |
| Financing Cash Flow | $7.5M | $19.3M | $272.5K | -$31.0K | $10.9M | $15.1M | $10.7M | $4.7M | $12.3M | $94.5M | $40.2M |
R&D Spending
R&D (TTM)
$775.8M
R&D Intensity
37.7%
R&D Growth vs Prior
+5028.2%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $4.1M | $4.6M | $4.9M | $3.18B | $2.06B | |
| R&D Expense | $573.7K | $2.0M | $4.3M | $5.8M | $6.6M | $7.3M | $3.7M | $3.2M | $2.9M | $15.1M | $775.8M | |
| R&D % of Revenue | — | — | — | — | — | 668.5% | 90.2% | 70.0% | 57.7% | 0.5% | 37.7% | |
| SG&A | $2.8M | $6.8M | $6.0M | $3.2M | $5.6M | $6.9M | $5.8M | $5.8M | $6.6M | $1.88B | $3.68B |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $4.1M | $4.6M | $4.9M | $3.18B | $2.06B | |
| Cost of Revenue | $96.1K | $122.9K | $123.2K | $183.1K | $0.00 | $545.9K | $2.7M | $3.5M | $3.2M | $2.47B | $1.75B | |
| Gross Profit | -$96.1K | -$122.9K | -$123.2K | -$183.1K | $0.00 | $543.5K | $1.4M | $1.1M | $1.7M | $709.8M | $306.8M | |
| R&D | $573.7K | $2.0M | $4.3M | $5.8M | $6.6M | $7.3M | $3.7M | $3.2M | $2.9M | $15.1M | $775.8M | |
| SG&A | $2.8M | $6.8M | $6.0M | $3.2M | $5.6M | $6.9M | $5.8M | $5.8M | $6.6M | $1.88B | $3.68B | |
| Operating Income | -$4.4M | -$9.0M | -$13.5M | -$9.2M | -$12.2M | -$13.8M | -$8.4M | -$8.1M | -$7.9M | -$9.9M | -$10.9M | |
| Interest Expense | $495.17 | $0.00 | $0.00 | $18.6K | $360.4K | $0.00 | $0.00 | $0.00 | $373.1K | $10.7K | $10.7K | |
| Pretax Income | -$4.5M | -$8.9M | -$13.3M | -$8.9M | -$12.6M | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$11.4M | -$12.4M | |
| Net Income | -$3.4M | -$8.9M | -$10.0M | -$8.9M | -$12.6M | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$12.6M | -$13.2M | |
| EPS (Diluted) | -8105.50 | -10321.20 | -12649.70 | -11612.10 | -9389.10 | -165820.00 | -649.20 | -201.40 | -83.60 | -31.20 | -33.05 | |
| EBITDA | -$3.4M | -$8.9M | -$10.3M | -$8.8M | -$12.1M | -$18.1M | -$7.3M | -$7.1M | -$7.3M | -$9.2M | -$10.0M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.10 | 0.42 | 0.55 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.2M | $18.4M | $9.8M | $5.8M | $9.1M | $8.0M | $11.8M | $9.0M | $15.1M | $2.2M | $1.09B | |
| Short-Term Investments | $0.00 | $1.8M | $3.9M | $42.4K | $57.5K | $57.7K | $0.00 | $0.00 | $0.00 | $39.6K | $40.3M | |
| Total Current Assets | $5.3M | $20.3M | $14.1M | $6.3M | $10.4M | $12.4M | $15.0M | $11.9M | $17.5M | $2.7M | $1.3M | |
| Total Assets | $6.4M | $21.3M | $15.1M | $7.8M | $12.1M | $16.5M | $18.7M | $16.2M | $21.2M | $3.0M | $1.3M | |
| Total Current Liabilities | $284.2K | $713.0K | $1.2M | $1.7M | $2.7M | $4.3M | $2.7M | $2.7M | $2.5M | $2.0M | $2.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $284.2K | $713.0K | $1.2M | $1.9M | $3.0M | $4.8M | $2.7M | $3.6M | $2.9M | $2.0M | $2.5M | |
| Stockholders' Equity | $6.1M | $20.6M | $13.9M | $5.9M | $9.1M | $11.7M | $16.0M | $12.6M | $18.3M | $1.1M | -$1.2M | |
| Retained Earnings | -$32.9M | -$39.0M | -$49.2M | -$64.6M | -$92.6M | -$120.3M | -$134.3M | -$149.2M | -$159.7M | -$130.2M | -$132.6M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.4M | -$3.7M | -$6.7M | -$7.4M | -$9.8M | -$15.6M | -$7.3M | -$7.0M | -$7.8M | -$8.64B | -$1.15B | |
| Capital Expenditure | -$19.5K | -$43.8K | -$27.0K | -$42.6K | -$1.7K | -$39.1K | -$161.8K | -$9.3K | $0.00 | $3.00 | $9.49 | |
| Free Cash Flow | -$2.4M | -$3.7M | -$6.7M | -$7.4M | -$9.8M | -$15.6M | -$7.4M | -$7.0M | -$7.8M | -$8.64B | -$1.15B | |
| Investing Cash Flow | -$19.5K | -$1.9M | -$2.8M | $3.8M | -$1.7K | -$673.0K | -$661.8K | -$9.3K | $0.00 | $0.00 | $2.4M | |
| Financing Cash Flow | $7.5M | $19.3M | $272.5K | -$31.0K | $10.9M | $15.1M | $10.7M | $4.7M | $12.3M | $94.5M | $40.2M | |
| Issuance of Stock | $8.3M | $20.3M | $207.6K | -$31.0K | $12.5M | $17.1M | $10.7M | $5.2M | $8.1M | $94.5K | -$108.9K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$290.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.2M | $2.4M | $3.1M | $0.00 | $610.2K | $697.9K | $278.2K | $137.7K | $119.3K | $106.9M | $193.9M | |
| Net Change in Cash | $5.1M | $13.3M | -$11.3M | -$4.0M | $1.6M | -$1.2M | $2.7M | -$2.3M | $4.5M | -$8.55B | -$1.11B |
Dilution Tracker
Shares outstanding grew 30879.2% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+30879.2%
Stock Issuance (TTM)
-$108.9K
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.10 | 0.42 | 0.55 | |
| Change vs Prior % | — | 47.0% | 20.3% | 0.6% | 28.7% | -91.7% | 10830.4% | 211.3% | 156.1% | 326.6% | 31.4% | |
| Stock Issuance | $8.3M | $20.3M | $207.6K | -$31.0K | $12.5M | $17.1M | $10.7M | $5.2M | $8.1M | $94.5K | -$108.9K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.2M | $2.4M | $3.1M | $0.00 | $610.2K | $697.9K | $278.2K | $137.7K | $119.3K | $106.9M | $193.9M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 49.9% | 33.9% | 23.9% | 34.5% | 22.3% | 14.9% | |
| Operating Margin % | — | — | — | — | — | -1266.0% | -202.6% | -176.9% | -160.2% | -0.3% | -0.5% | |
| Net Margin % | — | — | — | — | — | -1707.3% | -192.2% | -166.9% | -165.1% | -0.4% | -0.6% | |
| EBITDA Margin % | — | — | — | — | — | -1660.3% | -177.4% | -153.6% | -146.8% | -0.3% | -0.5% | |
| FCF Margin % | — | — | — | — | — | -1434.0% | -180.0% | -152.1% | -157.1% | -272.1% | -55.9% | |
| ROE % | -56.2% | -43.1% | -72.1% | -152.1% | -138.7% | -159.1% | -49.6% | -61.0% | -44.6% | -1168.4% | -264.3% | |
| ROA % | -53.7% | -41.6% | -66.4% | -114.6% | -104.6% | -113.0% | -42.5% | -47.5% | -38.5% | -414.5% | -1008.1% | |
| ROIC % | -71.4% | -43.5% | -97.4% | -147.7% | -128.7% | -108.5% | -50.7% | -58.5% | -41.0% | -920.5% | 912.8% | |
| R&D / Revenue % | — | — | — | — | — | 668.5% | 90.2% | 70.0% | 57.7% | 0.5% | 37.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 279.6% | 11.2% | 7.5% | 64167.3% | |
| Gross Profit | -13.0% | -27.8% | -0.3% | -48.6% | 100.0% | 0.0% | 158.1% | -21.5% | 55.0% | 41494.3% | |
| Operating Income | -88.7% | -105.2% | -50.6% | 32.3% | -33.0% | -13.3% | 39.2% | 2.9% | 2.7% | -25.0% | |
| Net Income | -87.2% | -158.3% | -12.7% | 10.7% | -41.5% | -47.0% | 57.3% | 3.4% | -6.3% | -53.9% | |
| EPS (Diluted) | -25.9% | -27.3% | -22.6% | 8.2% | 19.1% | -1666.1% | 99.6% | 69.0% | 58.5% | 62.7% | |
| Operating Cash Flow | -512.7% | -55.5% | -81.6% | -10.4% | -32.8% | -59.2% | 53.3% | 4.1% | -11.2% | -111185.8% | |
| Free Cash Flow | -516.3% | -56.1% | -80.2% | -10.6% | -32.0% | -59.5% | 52.3% | 6.0% | -11.0% | -111185.8% | |
| R&D Expense | 95.9% | 250.3% | 113.7% | 35.3% | 13.9% | 10.0% | -48.8% | -13.8% | -11.3% | 430.1% | |
| SG&A Expense | 88.9% | 145.3% | -12.3% | -47.4% | 75.9% | 23.7% | -14.8% | -0.8% | 13.1% | 28571.5% | |
| Total Assets | 402.1% | 232.9% | -29.4% | -48.2% | 55.0% | 36.1% | 13.5% | -13.5% | 31.3% | -85.7% | |
| Book Value / Share | 364.2% | 129.0% | -44.0% | -57.9% | 20.6% | 1437.6% | -98.7% | -74.7% | -43.2% | -98.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 5.3% | 206.3% | -49.2% | 153.7% | -23.3% | -100.0% | |
| Diluted Shares | 60.8% | 47.0% | 20.3% | 0.6% | 28.7% | -91.7% | 10830.4% | 211.3% | 156.1% | 326.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High0.00 / 0.42 / 0.64
P/B-7.10
10Y Low / Med / High0.02 / 4.13 / 7.44
EV/EBITDA108.33
10Y Low / Med / High0.37 / 1.23 / 1.50
EV/Revenue-0.53
P/FCFAt Loss
Intrinsic Value Models (per share)
Graham Net-Net
$2070.25
Cash / Share
$2074.83
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -6.75 | -12.07 | -4.37 | -3.61 | -1.69 | -0.01 | -0.29 | -0.25 | -0.39 | -0.50 | -0.47 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.55 | 0.42 | 0.64 | 0.00 | 0.00 | |
| P/B Ratio | 5.25 | 5.21 | 4.13 | 7.44 | 2.34 | 0.02 | 0.14 | 0.15 | 0.17 | 6.00 | -7.10 | |
| EV/EBITDA | -8.02 | -10.07 | -4.64 | -4.37 | -1.04 | 0.37 | 1.23 | 0.81 | 1.50 | -0.46 | 108.33 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.12 | -2.18 | -1.25 | -2.21 | 0.00 | -0.53 |
Analyst Estimates & Quality
Altman Z-Score
1409.03
Safe
Piotroski F-Score
1
Weak